Partnerships

Partnering to advance NK and CAR-NK therapies

BioNK welcomes scientific, clinical, manufacturing, regulatory, investment and business-development discussions with biotech, pharma, academic and public-health partners.

01 // Partnership Areas

Where we collaborate.

NK / CAR-NK platform development

Joint development of unmodified or engineered NK products.

Target discovery & validation

Indication-specific antigen and biology validation.

CMC & analytical development

Process, potency and analytical assay co-development.

Clinical development LatAm

Clinical trial planning and execution in Brazil and Latin America.

Manufacturing & cryologistics

Manufacturing capacity, cold-chain and logistics integration.

Regulatory & market access

Regulatory strategy and access pathway evaluation.

02 // What BioNK Brings

Differentiated capabilities.

  • ▪NK and CAR-NK development strategy
  • ▪Translational oncology focus
  • ▪Brazil/LatAm regulatory and clinical perspective
  • ▪Manufacturing and CDMO ecosystem access
  • ▪Advanced therapy commercialization discipline
  • ▪Strong IP and governance mindset
03 // Partnering Principles

How we operate.

  • ▪Patient safety first
  • ▪Evidence before claims
  • ▪IP protection
  • ▪Background IP and improvements clearly separated
  • ▪Phase-gated investment
  • ▪Transparent governance
  • ▪Compliance with anti-corruption and public integrity standards
  • ▪No unrestricted technology transfer without safeguards
Get in touch

Discuss a Collaboration

Reach out for scientific collaboration, business development, investor discussions or media inquiries.

Business Development & Partnerships
Dr. Valeria Povolotsky
Vice President Business Development, BioNK
+1 (973) 780-7988